Lv51
1280 积分 2022-03-23 加入
非小细胞肺癌MET临床检测中国专家共识
4小时前
待确认
Bulumtatug Fuvedotin (BFv, 9MW2821), a next-generation Nectin-4 targeting antibody-drug conjugate, in patients with advanced solid tumors: a first-in-human, open-label, multicenter, phase I/II study
5天前
已完结
Activating AKT1 and PIK3CA Mutations in Metastatic Castration-Resistant Prostate Cancer
6天前
已完结
Mutant-selective AKT inhibition through lysine targeting and neo-zinc chelation
6天前
已完结
Bulumtatug Fuvedotin (BFv, 9MW2821), a next-generation Nectin-4 targeting antibody-drug conjugate, in patients with advanced solid tumors: a first-in-human, open-label, multicenter, phase I/II study
7天前
已完结
Tisotumab Vedotin as Second- or Third-Line Therapy for Recurrent Cervical Cancer
7天前
已完结
Atezolizumab plus bevacizumab and chemotherapy for metastatic, persistent, or recurrent cervical cancer (BEATcc): a randomised, open-label, phase 3 trial
8天前
已完结
Pembrolizumab plus chemotherapy for advanced and recurrent cervical cancer: final analysis according to bevacizumab use in the randomized KEYNOTE-826 study
8天前
已完结
Pembrolizumab for Persistent, Recurrent, or Metastatic Cervical Cancer
8天前
已完结
First-Line Pembrolizumab + Chemotherapy Versus Placebo + Chemotherapy for Persistent, Recurrent, or Metastatic Cervical Cancer: Final Overall Survival Results of KEYNOTE-826
8天前
已完结
皖公网安备34019202002308
